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CausalityObjectives: To analyze and report adverse drug reactions (ADRs) in a tertiary care teaching hospital.
Methods: This was an observational study, conducted to analyze and communicate the ADRs reported
from July 2016 to June 2017 in a south Indian tertiary care teaching hospital. On daily basis, ADRs
reported by healthcare professionals (HCPs) were analyzed and the reports that meet pharmacovigilance
programme of India (PvPI) reporting criteria were communicated to PvPI through a specified updated
Indian Pharmacopoeia Commission (IPC) suspected ADR reporting form. In this study, ADRs were sum-
marised based on demographics, drug, incidence, type of reaction and its outcome. Causality, severity,
seriousness, and predictability were assessed through WHO causality assessment scale, Hartwig and
Siegel Severity Assessment Scale and PvPI criteria.
Results: A total of 254 ADRs communicated to PvPI through specified, updated IPC suspected ADR report-
ing form. The incidence of ADRs in both males and females was identical. The occurrence of ADRs in adult
patients (71.26%) was significantly higher than other age groups. Of total ADRs, most of them were with
Antibiotics (24.01%) followed by antipsychotics (11.42%). In causality assessment, a majority of ADRs
(48.82%) were considered possibly related to the drug or treatment and 55.12% were mild in severity.
Overall, 36.22% patients were recovered from ADRs. Most of the reported ADRs (54.33%) were probably
preventable.
Conclusions: The results provided an insight to the HCPs on the importance of monitoring and reporting
of ADRs. High-quality data gathered through a reporting system, most of the reported ADRs were prob-
ably preventable; the proper review of patient history and monitoring by HCPs can reduce the incidence
of ADR. Our study results emphasize a need for establishing a pharmacovigilance centre to ensure the safe
use of drugs.
 2018 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The development of drugs in the last decades has brought
remarkable benefits for the patients, at the same time the inci-
dence of Adverse Drug Reaction (ADR) has raised remarkably.
ADR is defined by World Health Organization (WHO) as ‘‘aresponse to a medicinal product which is noxious, unintended
and which occurs at doses normally used in man for prophylaxis,
diagnosis or therapy of disease or for the restoration, correction
or modification of physiological function”.1,2 It is universally
accepted that ‘‘No drug absolutely free from side effects”. From
the literature it is observed that 5% of all hospital admissions were
related to drug-induced problems and 10–20% of hospitalized
patients are developing ADRs, it is estimated that ADRs are the
fourth to the sixth leading cause of death.3
According to the WHO, ‘‘Pharmacovigilance is defined as the
science and activities relating to the detection, assessment, under-
standing, and prevention of adverse effects or any other possible
drug-related problem, particularly long-term and short-term
adverse effects of medicines”.4–7 Pharmacovigilance aims at
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data gathered through a reporting system. Good pharmacovigi-
lance helps in the minimization or prevention of ADRs through
early detection and effective communication, which ultimately
help each patient to receive optimum therapy. It can generate evi-
dence that will inspire public confidence and trust in drugs.8
ADRs are more common with the multiple drug therapy and
with each additional medication taken by the patient the hazard
of an ADR episode gets multiplied by 1.14 thereby directly increas-
ing the length of stay.9,10 ADRs may also result in the slackened
quality of life, increased physician visits, hospitalizations, and even
death. In addition, they result in increased health care costs. Thus
they place a substantial encumbrance on health care resources.7 A
study conducted in south Indian tertiary referral hospital revealed
that 0.7% of total admissions were drug-related and 1.8% fatal
ADRs.11
Therefore, medicines safety monitoring is an essential element
of the healthcare system and for high-quality medical care. Cur-
rently, WHO Collaborating Centre for International Drug Monitor-
ing (the Uppsala Monitoring Centre) has a strong network of 194
Member States worldwide,12 these states collects, reviews and
reports suspected ADRs, to the Uppsala Monitoring Centre for entry
into the WHO database (largest database of over 3.5 million case
reports).8
In India, in the year 2010 the Ministry of Health and Family
Welfare (MoHFW), launched the nationwide Pharmacovigilance
Programme of India (PvPI). Indian Pharmacopoeia Commission
(IPC) under the MoHFW has been functioning as the National Coor-
dination Centre (NCC) for PvPI since April 2011, since then rapid
progress in reporting of ADRs by the healthcare professionals is
seen.11 PvPI stated that during the period of April 2011 to March
2016, a total of 181,656 reports have been received through vari-
ous reporting modalities.13 Through this data PvPI regularly rec-
ommends the drug regulatory authorities and suggests the
Healthcare professionals (HCPs) in improving the safe use of drugs.
Still, there is a greater need to create and enhance awareness in
community and healthcare professionals about the importance of
close monitoring of drug outcomes especially newer ones. Aware-
ness regarding the detection, management, prevention, and report-
ing of ADR is utmost important in improving patient care and to
reduce cost. This present study is aimed to strengthen the ADR
database through analysis and reporting of ADRs and to improve
the reporting culture among HCPs.2. Methodology
An observational study was carried over a period of 12 months
from July 2016 to June 2017 in Rajiv Gandhi Institute of Medical
Sciences (RIMS) General hospital at Kadapa district, Andhra Pra-
desh, India.
Study site description:
A 750 bedded tertiary care government teaching hospital pro-
viding both in-patient and out-patient services with Medicine, Sur-
gery, OBG, Pediatrics, Orthopaedics, Psychiatry, Skin and VDL, ENT,
Ophthalmology. The average daily out-patient consultancy is 900–
1000 and in-patient is 100–120. On average 90–100 Pharm. D stu-
dents, 200–250 medical and 300–350 Nursing students will be
available in different departments for better patient care.
Ethical considerations:
This study was conducted after obtaining the ethical approval
from the institutional ethics committee of RIMS and with patient’s
permission.
Functioning of the ADR reporting system:
On daily basis, HCPs were informed regarding the importance of
monitoring and reporting of ADRs. At the time of admission, all thepatients were assessed for the previous allergies, ADRs, and past
medical history and were noted in the case sheets. The
symptoms/signs observed through the clinical review process were
assessed for their relation with the drug(s), if any new symptom(s)
experienced by the patient during the hospital stay (In-Patient)/
course of therapy (Out Patient) were suspected as drug-induced
and analyzed for their relationship with the drugs than with the
disease and its possible complications. If the reaction is not related
to the underlying disease and/or its complication or if the possible
causal relation is more with the drug than other possible causes,
then it will be suspected as an ADR and was confirmed with the
support of literature (if any). Such ADRs reported by the HCPs in
institutional suspected ADR reporting form and ADR notification
form were analyzed for their completeness, credibility, and cor-
rectness. Suspected ADRs that meet PvPI reporting criteria were
separated, reported and documented in PvPI suspected ADR
reporting form.14
We have also encouraged the patients and their caretakers to
report all ADRs using reporting modalities like directly reporting,
either to the treating physician or clerkship and internship practic-
ing students of Pharm D or Nurses.
Data were carefully evaluated for quality, based on the follow-
ing essential elements by analysing patient and reaction character-
istics: patient initials, gender, date of reaction (onset), description
of the reaction or problem, suspected medication(s), indications for
use, concomitant medical products including self-medication and
herbal remedies, de-challenge, re-challenge and outcomes.
After initial notification of a suspected ADR, additional details
were collected concerning previous allergies, concomitant medica-
tions, co-morbidities, ADR management and outcome, and other
details necessary for evaluation through direct interview with
the reporter and patients, and/or evaluation of patient medical
records.
These suspected ADRs were then reported to 3 PvPI ADR mon-
itoring centres (AMCs); Kurnool Medical College, Madras Medical
College or Sri Venkateswara Medical College. Care was taken to
avoid the duplication of reporting i.e., one ADR was reported to
one centre only. On monthly basis, we have received the acknowl-
edgments with unique numbers i.e. AMC number and Worldwide
Number of reported ADRs from these centres. The worldwide num-
ber and AMC number were entered into the documented reporting
forms and ADR database and the same was communicated to the
reporters.2.1. Evaluation of data
The reactions were categorized based on patient demographics
(age and gender) and ADR characteristics (the type of ADRs, drug
characteristics, system organ class, outcome and management,
de-challenge/re-challenge and reporter status).2.1.1. Patient demographics characteristics
The ADRs were summarized based on the patients’ age and gen-
der. Patients were divided into four age groups such as paediatrics
(0–12 years), adolescents (13–17 years), adults (18–65), and
geriatrics > 65.2.1.2. Adverse drug reaction characteristics
The ADRs were analyzed for their seriousness, severity, causal-
ity and the organ system affected.
The seriousness of the ADRs was assessed by using the PvPI
criteria14 i.e. life-threatening, required intervention to prevent per-
manent impairment/damage, hospitalization/prolonged hospital
stay, disability, congenital anomaly, and death.
Table 2
Analysis of ADR.














Not preventable 2 0.79%
Definitely preventable 114 44.88%
Probably preventable 138 54.33%
Seriousness$
No 90 35.43%
Hospitalization initial/prolonged 71 27.95%
Life-threatening 4 1.57%






* UMC-WHO Scale is used.
+ Hartwig and Siegel ADR Severity Assessment Scale.
# Modified Schumock and Thornton Preventability Scale.
$ As per PvPI Criteria.
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mild, moderate or severe according to the classification system of
Hartwig and Siegel Severity Assessment Scale.15
No single method was universally accepted for assessing the
causal relationship of the drug to adverse reactions as various algo-
rithms and methods are in use according to the individual prefer-
ence.16–18 Here, we have assessed the causality to establish the
relationship between the drug and the reaction by using WHO
Causality assessment scale, as it is recommended by Uppsala Mon-
itoring Centre (UMC) and PvPI.14,19,20 Preventability was assessed
using the classification system of modified Schumock and Thorn-
ton scale.21
Further, ADRs were categorized based on de-challenge/re-
challenge, class of the causative drug, outcomes, management of
ADR and the reporter status.
3. Results
A total of 254 reported/notified suspected ADRs from different
departments were analyzed and reported to PvPI. Reports were
scrutinized based on patient demographics, drug characteristics,
type of ADRs, outcomes, Causality, Severity, Preventability, and
seriousness.
3.1. Data evaluation based on demographics of the patient
Of the 254 ADRs 125 were experienced by males and 129 by
females patients. The incidence of ADRs among males and female
was similar. The majority (71.26%) of ADRs were reported in adults
then the geriatric (17.32%), pediatric (7.87%), and adolescent
(3.54%) patients. which was shown in Table 1.
3.2. Department wise distribution
Out of 254 ADRs, 56.6% ADRs were reported from the General
Medicine department followed by Psychiatry (13.38%), Dermatol-
ogy, Venerology and Leprosy (11.0%), ICU (4.72%), Pulmonology
(4.72%), Pediatrics (3.9%), Orthopedics (2.7%), Surgery (1.57%),
ENT (0.78%) and OBG (0.39%).
3.3. Analysis of ADRs
3.3.1. Causality
Upon causality we found the majority (48.82%) of the reported
ADRs were possible, followed by probable (27.17%), certain
(12.20%) and unassessable (11.42%), which was shown in Table 2.
3.3.2. Severity
Assessment of severity is essential to take necessary action
against the drug continuation, in our study most of the ADRs were
mild and only a few were severe. The severity distribution of ADRs
was represented in Table 2.Table 1
Distribution based on demographics.










Geriatrics 44 17.32%3.3.3. Preventability
Preventability assessment helps in improving drug use, out of
254 ADRs, most were probably preventable (54.33%) followed by
definitely preventable (44.88%) and only a few (0.7%) were not pre-
ventable and this was clearly showed in Table 2.3.3.4. Seriousness
Seriousness was assessed by using standard criteria given by
the PvPI and found the majority of them were serious (65%). Distri-
bution of ADRs based on seriousness in accordance with criteria
was demonstrated in Table 2.3.3.5. De-challenge and re-challenge
The causative drugs were withdrawn from the prescription
(dechallenge) in the majority of the cases i.e. 149 (58.7%), in 9
(3.5%) cases rechallenge was performed, and in remaining cases,
this information was lacking or de or re-challenge was not
performed.3.4. Drug class
A higher number of ADRs were reported for antibiotics 61
(24.01%) followed by antipsychotics 29 (11.42%) and analgesics
and antipyretics 19 (7.48%). Detailed list of offending drugs is
shown in detail in Table 3.3.5. System affected
We observed that 67 (26.4%) ADRs were related to Gastro-
Intestinal (GI) system organ class followed by Skin 61 (24.0%)
and Central Nervous System 37 (14.6), the involvement of other
systems is illustrated in Table 4.
Table 3
Characterization of drugs involved in ADRs.

























































ART ZLN (zidovudine, lamivudine, nevirapine) 4(1.574%)
TEL (Tenofovir, efavirenz, lamivudine) 4(1.574%)
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Table 4
Characterization of systems affected with ADRs.






Renal system 22 8.66%






Class of the drug Offending drug Total number of ADRs (%)
n = 254
Chlorpheniramine 1(0.394%)
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Among 254 patients, 92 (36.2%) patients have recovered from
the reactions and 78 (30.7%) were at recovering stage during the
study period while the outcomes of 52 (20.47%) patients were
unknown, 30 (11.81%) were not recovered and 1 ADR each was
fatal and continuing which were demonstrated in Table 5.
3.7. Management of ADRs
Out of 254, 144 (56.7%) patients have received treatment with
at least one additional drug for the reported ADR with or without
dechallenge, and in 54 (21.3%) patients offended/suspected drug
was withdrawn from the prescription and no treatment was given
for the ADR. Table 5 illustrate clearly the management of ADRs.Table 5
Characterization of ADRs based on outcome and management.











Addition of another drug with/without
dechallenge
144 56.69
Drug withdrew only 54 21.26
Substituted with another drug 6 2.36
No change 28 11.023
Dose reduced 13 5.12
No information 9 3.543.8. Reporter professional status
ADRs were reported by Pharm D students and other HCPs like
the physician, nurses. During the study period, we observed that
the majority of ADRs were reported by students (96.06%) followed
by physicians and nurses (3.93%).4. Discussion
PvPI gathers the ADRs from all healthcare setups and the public
in India, and communicates the significant data to drug regulatory
authorities for necessary action on the drugs; it also communicates
the healthcare professionals and the public regarding the risk of
ADRs, by this it improves the patient safety and welfare, and it is
the responsibility of all healthcare professionals to support the
PvPI in promoting safe use of medicine, in this view we have
reported a total of 254 ADRs to the PVPI through AMCs according
to the standard criteria given by National Coordinating Centre
(NCC) for monitoring ADR.
We have found no significant difference in the occurrence of
ADR among males (49.21%) and females (50.79%). Studies con-
ducted in northeast India by Lihite et al.,3 and in south Indian study
conducted by Vijayakumaret al.,22 have reported only 8% more
ADRs in females than in males.
The incidence of ADRs was more in adult population than pedi-
atrics, adolescents and geriatrics as this population was found to be
visiting frequently hospitals and drug usage is often more in them.
The generated results exhibited similarity with a certain popu-
lation6,9,23,25 and same were conflicted in another study22 which
justified that the geriatrics were more vulnerable population.
Majority of the ADRs were reported from the Department of
General Medicine than other departments, where the rate of con-
sultation is more than in the other departments, observational
studies conducted in India have also reported that most of the
ADRs identified were from the same the General medicine
Department.4,24,26,27
Causality assessment is essential to confirm whether the reac-
tion is because of drug alone or other factors also involved in
ADR occurrence, we did causality assessment using WHO-UMC
causality assessment scale and found that the majority of ADRs
were possible, other observational studies conducted in South
Indian tertiary care teaching hospitals4,23,29 have also reported that
the majority of the reported ADRs were possible with the same
scale.
Assessment of severity is also essential to take necessary action
against the drug continuation, in our study most of the ADRs were
mild, and fortunately, the incidence of severe ADRs is low, as in the
case of similar studies conducted by other researchers.9,22,23
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in our study, the majority of ADRs were of probably preventable,
which indicates that proper history taking and individualized drug
therapy can minimize these ADRs and most of the patients were
illiterates and they have not maintained their medical records
properly and also they were unaware of their previous ADR occur-
rence. Other Studies conducted in India have also reported that the
incidence of probably preventable ADRs is more.4,6
The seriousness of the reaction gives information on the risk
involved, which is an important parameter to be considered in
the marketing of drugs. The seriousness was assessed by using PvPI
criteria and found the majority of ADRs were serious reactions,
which required intervention to prevent permanent damage and
increased hospitalization. In an Indian study conducted by Sneha
et al.4 also reported that majority of the ADRs were led to the
Hospitalization/Prolonged (52.33%) and required intervention
(38.31%), a considerable number of serious ADRs were identified.
And in another Indian study conducted by Singh et al.9 reported
that 6.5% ADRs were of life-threatening.
In our study, the majority of ADRs were observed in admitted
patients, and antibiotics were involved in the majority of ADRs, this
is due to the reason, that almost all inpatients have received antibi-
otic therapy either for prophylactic or curative therapy. The results
were consistent with previous studies.4,6,9,22,23,25,28,29
In outcomes of the reactions, most of the patients have shown
recovery after the withdrawal of offending drug and/or with the
treatment of ADRs, and the outcome was unknown for a predom-
inant number of ADRs. Fortunately, only one fatal reaction was
noted in this study.
This study suggests that there is a need for spontaneous ADR
reporting from all the departments of this tertiary care hospital
for monitoring and assessment of ADRs. This study also warrants
further research for the development of possible intervention
strategies to reduce the burden of ADRs. The present study showed
a major reporting among student clinical pharmacists (Pharm D
clerkship and internship practicing students) with the continuous
education and motivation. Throughout the study period, clinical
pharmacists have actively monitored the patients and interacted
with the treating physicians regarding the outcomes of the treat-
ment to get complete information on the suspected ADRs. The
student clinical pharmacists were actively involved in the ADR
analysis and reporting to PvPI. Out of all 254 ADRs, only 10 were
reported by the physicians and the reporting rate was nil among
nurses. Most of the studies conducted in India9,23 and Saudi Ara-
bia30 have concluded under-reporting by physicians and Nurses.
But, studies in Brazil5,25 reported that physicians and nurses are
actively involved in ADR reporting.
There are various probable reasons identified for underreport-
ing such as lack of aptitude (physicians limited their role to
identifying and treating of ADRs, and only a few physicians have
extended their role to the reporting to the Pharmacovigilance cen-
tres), time constraint, non-accessibility of ADR (IPC) reporting
forms, lack of incentives (no encouragement to the physicians in
reporting ADRs with the form of appreciation letters/credits) etc.
A Study conducted in northeast India3 has also stated the same rea-
sons for underreporting.
But all the health care professionals provided their support in
confirming the ADR. In our study centre, ADR database mainte-
nance is almost nil; this could be mainly due to lack of strong
arrangements like drug safety monitoring system which could
guide and encourage the healthcare professionals in monitoring
and communicate ADRs. Though, PvPI and Medical Council of India
insisting an active drug safety monitoring system in every Govern-
ment and Private hospitals, most of the hospitals are not showing
complete interest in the establishment of an ADR monitoring
centre.5. Conclusion
This study concluded that the spontaneous reporting of ADRs is
fairly good in this hospital. Although the ADRs in the present study
were serious and preventable, monitoring and management of
such ADRs through therapeutic interventions would be beneficial
in better patient care. Hence clinical pharmacists have an impor-
tant responsibility in monitoring and reporting of ADRs. During
this study period, we have encouraged all the HCPs in the monitor-
ing and reporting of ADRs. With continuous awareness and moti-
vation, reporting culture can be improved; this can be achieved
through a well -structured and dedicated pharmacovigilance sys-
tem running by a clinical pharmacist. Pharm. D graduates can visit
all the departments and encourages HCPs by conducting aware-
ness and/ training programs on ADR reporting.
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